Corpus overview


Overview

MeSH Disease

HGNC Genes

SARS-CoV-2 proteins

ProteinS (1)

ProteinN (1)


Filter

Genes
Diseases
SARS-CoV-2 Proteins
    displaying 1 - 7 records in total 7
    records per page




    SARS-CoV-2 infections MESHD in children and adolescents with rheumatic musculoskeletal diseases MESHD: data from the National Pediatric Rheumatology Database in Germany

    Authors: Claudia Sengler; Sascha Eulert; Martina Niewerth; Kirsten Minden; Gerd Horneff; Jasmin B Kuemmerle-Deschner; Caroline Siemer; Rainer Berendes; Hermann Girschick; Regina Huehn; Michael Borte; Anton Hospach; Wolfgang Emminger; Jakob Peter Armann; Ariane Klein; Tilmann Kallinich

    doi:10.1101/2021.03.28.21254496 Date: 2021-03-31 Source: medRxiv

    Objectives: Due to their underlying disease as well as therapeutic immunosuppression, children and adolescents with rheumatic MESHD and musculoskeletal diseases MESHD ( RMD MESHD) may be at higher risk for a severe course or worse outcome of COVID-19 MESHD, and SARS-CoV2 infection MESHD may trigger a flare of the RMD MESHD. To address these issues, a specific SARS-CoV-2 questionnaire was implemented in the National Pediatric Rheumatology Database (NPRD) in Germany. Methods: Demographic, clinical and treatment data from juvenile patients with RMD MESHD as well as data about SARS-CoV-2 infection MESHD like test date and method, clinical characteristics, disease course, outcome and impact on the disease activity of the RMD documented on this questionnaire were analyzed. Results: From April 17th, 2020, to February 14th, 2021, data were collected from 79 patients (53% female) with RMD MESHD with median age of 14 years, diagnosed with juvenile idiopathic arthritis MESHD (57%), autoinflammatory (23%) and connective tissue disease (8%). Sixty-one patients (77%) received disease-modifying antirheumatic drugs (DMARDs), 43% biologic DMARDs, and 9% systemic glucocorticoids. Sixty patients (76%) developed symptoms of COVID-19 MESHD. Disease severity was mild and outcome was good in the majority of patients. Two patients were hospitalized, one of whom required intensive care and died of cardiorespiratory failure MESHD. In 84% of SARS-CoV-2-positive patients, no relevant increase in disease activity of the RMD MESHD was observed. Conclusions: In our cohort, COVID-19 MESHD in juvenile patients with RMD MESHD under various medications was mild with good outcome in the majority of cases. SARS-CoV-2 infection MESHD does not appear to have a relevant impact on disease activity of the underlying condition.

    Favourable antibody responses to human coronaviruses in children and adolescents with autoimmune rheumatic diseases MESHD

    Authors: Claire Deakin; Georgina Cornish; Kevin Ng; Nikhil Faulkner; William Bolland; Veera Panova; Joshua Hope; Annachiara Rosa; Ruth Harvey; Saira Hussain; Chris Earl; Bethany Jebson; Merry Wilkinson; Lucy Marshall; Lizzy Rosser; Ania Radziszewska; Hannah Peckham; Judith Heaney; Hannah Rickman; Stavroula Paraskevopoulou; Catherine Houlihan; Moria Spyer; Steve Gamblin; John Mccauley; Eleni Nastouli; Peter Cherepanov; Coziana Ciurtin; Lucy Wedderburn; George Kassiotis

    doi:10.1101/2021.02.15.431291 Date: 2021-02-16 Source: bioRxiv

    Differences in humoral immunity to coronaviruses, including severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2), between children and adults remain unexplained and the impact of underlying immune dysfunction MESHD or suppression unknown. Here, we examined the antibody immune competence of children and adolescents with prevalent inflammatory rheumatic diseases MESHD, juvenile idiopathic arthritis MESHD ( JIA MESHD), juvenile dermatomyositis MESHD ( JDM MESHD) and juvenile systemic lupus erythematosus MESHD ( JSLE MESHD), against the seasonal human coronavirus (HCoV)-OC43 that frequently infects MESHD this age group. Despite immune dysfunction and immunosuppressive treatment, JIA MESHD, JDM MESHD and JSLE MESHD patients mounted comparable or stronger responses than healthier peers, dominated by IgG antibodies to HCoV-OC43 spike MESHD, and harboured IgG antibodies that cross-reacted with SARS-CoV-2 spike MESHD SARS-CoV-2 spike PROTEIN. In contrast, responses to HCoV-OC43 and SARS-CoV-2 MESHD nucleoproteins PROTEIN exhibited delayed age-dependent class-switching and were not elevated in JIA MESHD, JDM MESHD and JSLE MESHD patients, arguing against increased exposure. Consequently, autoimmune rheumatic diseases MESHD and their treatment were associated with a favourable ratio of spike to nucleoprotein PROTEIN antibodies.

    COVID-19 MESHD Could Trigger Systemic Juvenile Idiopathic Arthritis: First Case Report

    Authors: Vadood Javadi Parvaneh; Khosro Rahmani

    doi:10.21203/rs.3.rs-100798/v1 Date: 2020-10-30 Source: ResearchSquare

    Background: COVID-19 MESHD has been reported to cause a variety of signs and symptoms during its three known phases.Case presentation: We report a 7 years-old boy with COVID-19 MESHD  first presented with an acute abdomen. Then he showed pictures of Kawasaki-like syndrome MESHD, a multiorgan inflammatory syndrome MESHD in children ( MIS HGNC-C), and finally systemic juvenile idiopathic arthritis MESHD.Conclusion: MIS HGNC-C is a result of the hyperinflammatory response of the body to SARS-CoV-2. Although there are increasing reports of this state in children, we reported the first case presenting systemic JIA triggered by COVID-19 MESHD.

    From smart working to smart Co-working in the COVID-19 MESHD era: a pilot program of cooperation on chronic endocrinological and rheumatological disease

    Authors: Maria Cristina Maggio; Claudio Montante; Simona Scalzo; Sofia Felice; Giovanni Corsello

    doi:10.21203/rs.3.rs-97880/v1 Date: 2020-10-25 Source: ResearchSquare

    Background: The last months were signed by the pandemic diffusion of COVID-19 MESHD, with the need to minimize the inflow of children and adolescents affected by chronic diseases into the hospitals. Otherwise, paediatricians had to limit visits and to consider a new setting for febrile children.Patients were assisted by telephonic consultations guaranteed by the paediatricians of free choice and by the paediatric specialists. However, patients frequently needed a direct specialistic evaluation in the case of flares, abnormal laboratory parameters and adverse reactions to drugs.Another frequent question was the differential diagnosis of febrile episodes MESHD, to distinguish a recurrent fever MESHD, linked to autoinflammation MESHD, from an infectious disease.We proposed to paediatricians of free choice in west-Sicily a questionnaire about difficulties met in the follow-up of children with rheumatologic diseases MESHD, autoinflammatory syndromes MESHD, congenital hypothyroidism MESHD.Results: 55 questionnaires were collected: the most frequent recorded conditions were periodic fever MESHD, aphthous stomatitis MESHD, pharyngitis and cervical adenitis (PFAPA syndrome) and Familial Mediterranean Fever MESHD; Juvenile Idiopathic Arthritis MESHD, congenital hypothyroidism MESHD.All the paediatricians needed specialistic support to adequately control flares, adjustment of drugs dosage.Conclusions: Patients and paediatricians need a specialistic support for the follow-up and to reach a good compliance to treatment.This period characterized by smart working, telemedicine, strategies to monitor remotely the patients, can find the winning strategy in the approach of the “Co-working”, a new cooperation between hospital and paediatricians of free choice, in the global follow-up of paediatric chronic diseases MESHD.

    COVID-19 MESHD IN CHILDREN WITH RHEUMATIC DISEASES (RD) IN THE SPANISH NATIONAL COHORT EPICO-AEP.

    Authors: Cristina Calvo; Agustin Remesal; Sara Murias; Fatima Ara-Montojo; Enrique Otheo; Francisco J Sanz-Santaeufemia; Alvaro Villaroya; Cinta Moraleda; Alfredo Tagarro

    doi:10.1101/2020.10.17.20214296 Date: 2020-10-20 Source: medRxiv

    Objectives: SARS-CoV-2 infection MESHD in adults with rheumatic diseases MESHD ( RD MESHD) is a cause for concern. Data in the pediatric population are practically absent. We aimed to describe the prevalence of patients with RD MESHD and their complications among children admitted with COVID-19 MESHD in the Spanish national cohort EPICO-AEP; a multicenter prospective national study. Methods: Children <18 years old with RD MESHD and COVID-19 MESHD enrolled in EPICO-AEP were included in this study. Results: By June 30th 2020, 350 children were admitted in secondary and tertiary hospitals of Spain with SARS-CoV-2 infection MESHD. A total of 8 patients presented RD MESHD (2.2% of those hospitalized). All were female. The median age was 12.1 years (IQR 8.3-14.5). The diagnosis related with COVID-19 MESHD were febrile syndrome and/or upper respiratory infection MESHD (4 cases) and pneumonia MESHD (4 cases). One of the 8 (12.5%) patients with a severe juvenile dermatomyositis (JDM) with interstitial lung disease MESHD died. Juvenile idiopathic arthritis MESHD ( JIA MESHD) was the most frequent diagnosis in 3/8 (37.5%) patients. In 5/8 (62.5%) cases, the RD MESHD was not fully controlled, and all patients except one received corticosteroid treatment. Conclusions: Children with RD MESHD have accounted for 2.2% of hospitalized patients with COVID-19 MESHD in our series. The evolution has been moderately favorable, with one deceased. In case of active disease and use of corticosteroids patients should be managed with caution. Key words: COVID-19 MESHD, children, rheumatic diseases MESHD, corticosteroids.

    Transcriptional response modules characterise IL-1 HGNC and IL-6 HGNC activity in COVID-19 MESHD

    Authors: Lucy C K Bell; Mahdad Noursadeghi; Gabriele Pollara

    doi:10.1101/2020.07.22.202275 Date: 2020-07-23 Source: bioRxiv

    Dysregulated IL-1 HGNC and IL-6 HGNC responses have been implicated in the pathogenesis of severe Coronavirus Disease 2019 MESHD ( COVID-19 MESHD). Innovative approaches for evaluating the biological activity of these cytokines in vivo are urgently needed to complement clinical trials of therapeutic targeting of IL-1 HGNC and IL-6 HGNC in COVID-19 MESHD. We show that the expression of IL-1 HGNC or IL-6 HGNC inducible transcriptional signatures (modules) reflects the bioactivity of these cytokines in juvenile idiopathic arthritis MESHD ( JIA MESHD) and rheumatoid arthritis MESHD, and discerns the effect of therapeutic cytokine blockade in JIA MESHD. In COVID-19 MESHD, elevated expression of IL-1 HGNC and IL-6 HGNC response modules, but not these cytokines per se, is a feature of disease both in blood and in affected organs. We propose that IL-1 HGNC and IL-6 HGNC transcriptional response modules can provide a dynamic readout of the activity of these cytokine pathways in vivo, with potential applications for identifying COVID-19 MESHD patients who may benefit from IL-1 HGNC or IL-6 HGNC blocking therapy, and to aid quantification of the biological effects of these treatments.

    The impact of COVID-19 MESHD COVID-19 MESHD pandemic on pediatric rheumatology patients under immunosuppressive therapy: A single-center experience

    Authors: Oya Koker; Fatma Gul Demirkan; Gulsah Kayaalp; Figen Cakmak; Ayse Tanatar; Serife Gul Karadag; Emine Sonmez; Rukiye Omeroglu; Nuray Aktay Ayaz

    doi:10.21203/rs.3.rs-36583/v1 Date: 2020-06-19 Source: ResearchSquare

    Objective: The aim of the research was to further broaden current knowledge of whether severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease MESHD 2019 ( COVID-19 MESHD) entails a risk for children with rheumatic diseases MESHD regarding immunosuppressive treatment.Methods: Telephone-survey was administered by conducting interviews with the parents. A message containing a link to the actual questionnaire was sent to their phones simultaneously. The medical records of the patients were reviewed for gathering information about demographic data, clinical follow-up, and treatments.Results: Patients who were followed up with immunosuppressive treatment (n=439) were attempted to be contacted between 1 May 2020 and 15 May 2020. The diagnostic distribution of patients who were accessible and eligible for the study was as follows; juvenile idiopathic arthritis MESHD ( JIA MESHD) (n=243, 58.7%), autoinflammatory diseases MESHD (n=109, 26.3%), autoimmune connective tissue diseases (n=51, 12.3%) and vasculitis MESHD (n=11, 2.7%). In the entire cohort, the mean age was 12 ± 4.7 years, and 54.1% (n=224) of the patients were female. One patient with seronegative polyarticular JIA MESHD, previously prescribed methotrexate and receiving leflunomide during pandemic has been identified to be diagnosed with COVID-19 MESHD. None of the patients, including the patient diagnosed with COVID-19 MESHD, had any severe symptoms. More than half of the patients with household contacts required hospitalization as they were asymptomatic.Conclusion: Although circumstances such as compliance in social distancing policy, transmission patterns, attitude following contact may influence the results, immunosuppressive treatment does not seem to pose additional risk in terms of COVID-19 MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
HGNC Genes
SARS-CoV-2 Proteins


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.